Inhibrx Biosciences Business Summary

Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and milestone payments, with a long-term model focused on the commercialization of proprietary biologic therapeutics. The company’s primary business segments are centered on oncology and orphan diseases, leveraging its proprietary single-domain antibody (sdAb) platform to engineer multivalent therapeutic candidates. Key pipeline assets include ozekibart (INBRX-109), a tetravalent DR5 agonist currently in registrational trials for chondrosarcoma, and INBRX-106, an OX40 agonist targeting solid tumors. In the competitive landscape, Inhibrx contends with firms such as Scholar Rock, Crinetics Pharmaceuticals, and TG Therapeutics; it distinguishes itself through its high-valency engineering capabilities that optimize agonist function, positioning it as a specialized leader in the next-generation antibody-drug market. The company is led by Co-founder and CEO Mark Lappe, a veteran biotechnology executive with over 30 years of experience in investment management and executive recruiting, formerly the founder of Efficacy Biotech Fund. The leadership team includes President David Matly, who brings extensive commercial launch expertise from Novartis, and Chief Financial Officer Kelly Deck, who oversees the firm’s capital strategy. Following the 2025 departure of co-founder Brendan Eckelman, Dr. Carlos Bais serves as Chief Scientific Officer, bringing deep expertise in translational sciences and oncology drug development. Inhibrx is backed by a robust roster of institutional investors, including BlackRock, Vanguard Group, and Sofinnova Investments, and maintains a board of directors featuring industry experts such as Douglas Forsyth and Dr. Kristiina Vuori.